Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions
Daniel G. Stover(Harvard University), Maryam B. Lustberg(Yale Cancer Center), Katlyn Tolliver(The Ohio State University), Robert Wesolowski(The Ohio State University Wexner Medical Center), Cynthia Timmers(Cancer Genetics (United States)), James L. Chen(Mayo Clinic), Nicole Williams(The Ohio State University), Erin Macrae(McGill University), Katharine A. Collier(The Ohio State University), Charles L. Shapiro(Tisch Hospital), Clara N. Lee(University of North Carolina at Chapel Hill), Jeffrey VanDeusen(The Ohio State University), Sagar Sardesai(The Ohio State University Wexner Medical Center), Susan Gillespie(The Ohio State University), Bhuvaneswari Ramaswamy(The Ohio State University), Mathew Cherian(The Ohio State University Wexner Medical Center), Raquel E. Reinbolt(The Ohio State University), Siraj M. Ali(UPMC Hillman Cancer Center), Sarah Asad(The Ohio State University), Anne M. Noonan(The Ohio State University), Elizabeth Adams(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Mahmoud Abdel‐Rasoul(The Ohio State University)
Cited by 18
Related Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
|Nature|2016|629
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
|Cancer Immunology Research|2016|493
Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells
|Proceedings of the National Academy of Sciences|2017|373